Risk of thrombogenicity among nonionic radiocontrast agents

Journal of Invasive Cardiology

Volumn 20, Issue 7, 2008, Pages 349-353

  Georgakis, Alexander ^a   Ener, Rasih Atilla ^a,b   Jin, Jianguo ^a   Kunapuli, Satya ^a   Fiss, David ^a   Leech, Stephen H ^a   Wolf, Nelson M ^a   Van Decker, William A ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Calcium secretion; Cardiac catheterization; Contrast media; Outcomes; Platelet aggregation; Platelet reactivity; Radiologic imaging; Thrombogenicity

Indexed keywords

ADENOSINE DIPHOSPHATE; ALANYLTYROSYLPROLYLGLYCYLLYSYLPHENYLALANINAMIDE; ALBUMIN; CALCIUM; IODIXANOL; IOHEXOL; IONIC CONTRAST MEDIUM; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXILAN; METRIZAMIDE; NONIONIC CONTRAST MEDIUM; PROTEINASE ACTIVATED RECEPTOR 4;

ARTICLE; BLEEDING TIME; BLOOD OSMOLARITY; CALCIUM MOBILIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; KIDNEY DISEASE; NORMAL HUMAN; OSMOLARITY; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RISK ASSESSMENT; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENICITY;

BLOOD PLATELETS; CONTRAST MEDIA; CORONARY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART CATHETERIZATION; HUMANS; IOHEXOL; IOPAMIDOL; PLATELET AGGREGATION; RISK FACTORS; TRIIODOBENZOIC ACIDS;

EID: 48149109102     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bonnemain B, Guerber M. (The history of lipiodol 1901-1994, or how a medication may evolve with the times). Rev His Pharm 1995;42:159-170.
2. Doby T. A tribute to Sven-Ivar Seldinger. Am J Roentgenol 1984;142:1-4.
3. McClennan BL, Preston M. Hickey memorial lecture. Ionic and non-ionic iodinated contrast media: Evolution and strategies for use. Am J Roentgenol 1990;155:225-233.
4. Esplugas E, Cequier A, Jara F, et al. Risk of thrombosis during coronary angioplasty with low osmolality contrast media. Am J Cardiol 1991;68:1020-1024.
5. Hwang MH, Piao ZE, Murdock DK, et al. The potential risk of thrombosis during coronary angiography using nonionic contrast media. Cathet Cardiovasc Diagn 1989;16:209-213.
6. Voeltz MD, Nelson MA, McDaniel MC, Manoukian SV. The important properties of contrast media: Focus on viscocity. J Invasive Cardiol 2007;19(Suppl A):1A-9A.
7. Albanese JR, Venditto JA, Patel GC, Ambrose JA. Effects of ionic and nonionic contrast media on in vitro and in vivo platelet activation. Am J Cardiol 1995;76:1059-1063.
8. LeFeuvre C, Batisse A, Collet JP, et al. Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty. Catheter Cardiovasc Interv 2006;67:852-858.
9. Stormorken H. Sakariassen KS. In vitro platelet degranulation by contrast media: Clinical relevance? [comment] Circulation 1994;90:1580-1581.
10. Chronos NA, Godall AH, Wilson DJ, et al. Profound platelet degranulation is an important side effect of some types of contrast media used in interventional cardiology [comment]. Circulation 1993;88:2035-2044.
11. Dalby MC, Davidson SJ, Burman JF, et al. Systemic platelet effects of contrast media: Implications for cardiologic research and clinical practice. Am Heart J 2002;143:E1.
12. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985;260:3440-3450.
13. Aquejouf O, Doutremepuich F, Azougagh OF, Doutremepuich C. Thrombogenicity of ionic and non-ionic contrast media tested in a laser induced rat thrombosis model. Thromb Res 1995;77:259.
14. Ardissini D, Merlini PA, Coppola R, et al. Tissue factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769.
15. Rao AK, Rao VM, Willis J, et al. Inhibition of platelet function by contrast media: Iopamidol and ioxaglate versus iothalamate. Radiology 1985;156;311-313.